
---
nice.evidencecategory: 
---

### Evidence Statement CG66ES175
An RCT291 reported that end-of-treatment LDL-C levels increased by 3% to a mean of 98.6 mg/dl (2.5 mmol/l) in patients who continued atorvastatin 10 mg, while a further reduction of 19% to a mean of 77.0 mg/dl (2.0 mmol/l) was observed in those assigned to atorvastatin 80 mg (p <0.0001). Level 1++

[@Shepherd_2006]

